Abstract PR008: Armed Myxoma virus demonstrates therapeutic activity in pre-clinical xenograft models
2021
Oncolytic Viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system. This represents a promising therapeutic option for cancer patients that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Poxviridae family of double stranded DNA viruses. The natural host of MYXV is a subset of lagomorphs, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins making it an excellent oncolytic virus for introduction of immunomodulatory proteins. The current work describes the oncolytic activity, transgene production capability, and in vivo activity of armed myxoma viruses in human cancer models. This abstract is also being presented as PO090. Citation Format: Lino E. Torres-Dominguez, Lina S. Franco, Mario Abrantes, Benjamin S. Walker, Zachary Tacner, Cassandra Kien, Anna K. Waters, Grant McFadden, Steven J. Potts, Leslie L. Sharp. Armed Myxoma virus demonstrates therapeutic activity in pre-clinical xenograft models [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr PR008.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI